Sigrima 420mg Injection

Sigrima 420mg Injection, is a targeted therapy containing the active constituents pertuzumab and trasrtuzumab. It is used to treat a type of breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body (metastasized) or cancer that has come back after the treatment. It will also be given before or after the surgery if the cancer has not metastasized. Cancer occurs when cells begin to grow abnormally in an uncontrolled manner.

breast cancer & non-small cell lung cancer

Sigrima 420mg Injection is a medication administered intravenously (IV) by a healthcare professional. It is important to follow the healthcare provider's instructions regarding the dosage and administration of medication

Human epidermal growth factor receptor 2 protein is largely present in some cancer cells and stimulates the growth of cancer cells. Sigrima 420mg Injection binds selectively to the HER2 receptors on breast cancer cells' surface, blocks them from receiving growth signals, and stops the cancer cells' growth.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

cold chain

1 vial (14ml)